Abstract
A wide range of highly effective genetically engineered biological preparations introduced into clinical rheumatology in recent years causes a special interest in their safety.Purpose of the study. Evaluation of the safety of infliximab therapy in patients with rheumatoid arthritis.Materials and methods. The authors' own data, which analyzed the undesirable effects of infliximab in 135 patients with rheumatoid arthritis in actual clinical practice, are presented. A case report of the adverse reaction of combination therapy with leflunomide and infliximab is presented.Results and its discussion. The overall tolerability of infliximab was satisfactory. Adverse events were observed in 28.1 % of cases, including 19.1 % of patients (14.1 %) had serious side effects that required discontinuation of the drug.Findings. In most cases, infliximab is safe for use in actual clinical practice. Patients should be informed about the risks of undesirable effects and the need for a rheumatologist's examination before each infliximab administration before prescribing therapy.
Highlights
Summary A wide range of highly effective genetically engineered biological preparations introduced into clinical rheumatology in recent years causes a special interest in their safety
The authors' own data, which analyzed the undesirable effects of infliximab in 135 patients with rheumatoid arthritis in actual clinical practice, are presented
Infliximab is safe for use in actual clinical practice
Summary
The authors' own data, which analyzed the undesirable effects of infliximab in 135 patients with rheumatoid arthritis in actual clinical practice, are presented. У одной пациентки во время четвертой инфузии ИНФ развился коллапс с выраженной миалгией и артралгией. У двух пациентов ИНФ был отменен в связи с возникновением тяжелой одышки во время введения препарата. У 3 пациентов имело место гнойное поражение суставов: у 2 больных наблюдалось развитие гнойного артрита (у одной пациентки после шестой инфузии, у другой — после восьмой), в обоих случая по‐ требовались госпитализация и дли‐ тельное лечение. После четвертого введения ИНФ в феврале 2010 года при объективном осмотре была обнаружена незудящая сыпь по типу пятен багрово-красно‐ го цвета в подмышечных областях симметрично Пациентке было проведено еще две инфузии ИНФ (последняя в июне 2010 года), на этом фоне высыпания оставались визуально без изменений. Пациентка наблюдалась в течение по‐ лугода, состояние кожных покровов оставалось без значительной динамики
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
